Literature DB >> 24225078

Immune activation, HIV persistence, and the cure.

Daniel C Douek1.   

Abstract

HIV infection is characterized by persistent immune activation, even in the context of suppressive antiretroviral therapy. This persistent activation, which appears to be fueled by microbial translocation from the gut resulting from HIV-related damage, is associated with deficits in immune function that in turn contribute to persistent activation. The presence of latent HIV reservoirs in lymphoid tissues also provokes immune activation in the context of immune suppression, resulting in expansion of the viral reservoir and potential viral replication, even with suppressive antiretroviral therapy. Therapeutic strategies are being devised to reduce persistent immune activation and limit the size of the HIV reservoir. This article summarizes a presentation by Daniel C. Douek, MD, PhD, at the IAS-USA continuing education program held in San Francisco, California, in March 2013.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24225078      PMCID: PMC6148844     

Source DB:  PubMed          Journal:  Top Antivir Med        ISSN: 2161-5853


  16 in total

Review 1.  Anatomical basis of tolerance and immunity to intestinal antigens.

Authors:  Allan McI Mowat
Journal:  Nat Rev Immunol       Date:  2003-04       Impact factor: 53.106

2.  Mucosal correlates of isolated HIV semen shedding during effective antiretroviral therapy.

Authors:  P M Sheth; T J Yi; C Kovacs; K S Kemal; R B Jones; B Osborne; R Pilon; C la Porte; M Ostrowski; T Mazzulli; H Burger; B Weiser; R Kaul
Journal:  Mucosal Immunol       Date:  2012-02-08       Impact factor: 7.313

Review 3.  Towards an HIV cure: a global scientific strategy.

Authors:  Steven G Deeks; Brigitte Autran; Ben Berkhout; Monsef Benkirane; Scott Cairns; Nicolas Chomont; Tae-Wook Chun; Melissa Churchill; Michele Di Mascio; Christine Katlama; Alain Lafeuillade; Alan Landay; Michael Lederman; Sharon R Lewin; Frank Maldarelli; David Margolis; Martin Markowitz; Javier Martinez-Picado; James I Mullins; John Mellors; Santiago Moreno; Una O'Doherty; Sarah Palmer; Marie-Capucine Penicaud; Matija Peterlin; Guido Poli; Jean-Pierre Routy; Christine Rouzioux; Guido Silvestri; Mario Stevenson; Amalio Telenti; Carine Van Lint; Eric Verdin; Ann Woolfrey; John Zaia; Françoise Barré-Sinoussi
Journal:  Nat Rev Immunol       Date:  2012-07-20       Impact factor: 53.106

4.  Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.

Authors:  Josep M Llibre; Maria J Buzón; Marta Massanella; Anna Esteve; Viktor Dahl; Maria C Puertas; Pere Domingo; Josep M Gatell; Maria Larrouse; Mar Gutierrez; Sarah Palmer; Mario Stevenson; Julià Blanco; Javier Martinez-Picado; Bonaventura Clotet
Journal:  Antivir Ther       Date:  2011-09-28

5.  The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.

Authors:  Alejandro Vallejo; Carolina Gutierrez; Beatriz Hernandez-Novoa; Laura Diaz; Nadia Madrid; María Abad-Fernandez; Fernando Dronda; María J Perez-Elias; Javier Zamora; Eduardo Muñoz; María A Muñoz-Fernandez; Santiago Moreno
Journal:  AIDS       Date:  2012-09-24       Impact factor: 4.177

6.  Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.

Authors:  Steven A Yukl; Amandeep K Shergill; Kenneth McQuaid; Sara Gianella; Harry Lampiris; C Bradley Hare; Mark Pandori; Elizabeth Sinclair; Huldrych F Günthard; Marek Fischer; Joseph K Wong; Diane V Havlir
Journal:  AIDS       Date:  2010-10-23       Impact factor: 4.177

Review 7.  HIV infection and the gastrointestinal immune system.

Authors:  J M Brenchley; D C Douek
Journal:  Mucosal Immunol       Date:  2008-01       Impact factor: 7.313

8.  Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.

Authors:  Gero Hütter; Daniel Nowak; Maximilian Mossner; Susanne Ganepola; Arne Müssig; Kristina Allers; Thomas Schneider; Jörg Hofmann; Claudia Kücherer; Olga Blau; Igor W Blau; Wolf K Hofmann; Eckhard Thiel
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

9.  T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.

Authors:  Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Barry Bredt; Elilta Hagos; Harry Lampiris; Steven G Deeks
Journal:  J Infect Dis       Date:  2003-04-23       Impact factor: 5.226

Review 10.  Immune activation and HIV persistence: implications for curative approaches to HIV infection.

Authors:  Nichole R Klatt; Nicolas Chomont; Daniel C Douek; Steven G Deeks
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

View more
  13 in total

Review 1.  Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?

Authors:  A Saez-Cirion; B Jacquelin; F Barré-Sinoussi; M Müller-Trutwin
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-05-12       Impact factor: 6.237

2.  Detectability of HIV Residual Viremia despite Therapy Is Highly Associated with Treatment with a Protease Inhibitor-Based Combination Antiretroviral Therapy.

Authors:  Dolores Vaira; Michel Moutschen; Gilles Darcis; Nathalie Maes; Alexander O Pasternak; Anne-Sophie Sauvage; Frédéric Frippiat; Christelle Meuris; Françoise Uurlings; Marianne Lecomte; Philippe Léonard; Majdouline Elmoussaoui; Karine Fombellida
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

3.  Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T cell expansion in HIV infection.

Authors:  M-A Jenabian; M Patel; I Kema; K Vyboh; C Kanagaratham; D Radzioch; P Thébault; R Lapointe; N Gilmore; P Ancuta; C Tremblay; J-P Routy
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

Review 4.  The respiratory microbiome of HIV-infected individuals.

Authors:  M B Lawani; A Morris
Journal:  Expert Rev Anti Infect Ther       Date:  2016-08       Impact factor: 5.091

Review 5.  Gut epithelial barrier dysfunction in human immunodeficiency virus-hepatitis C virus coinfected patients: Influence on innate and acquired immunity.

Authors:  Mercedes Márquez; Clotilde Fernández Gutiérrez del Álamo; José Antonio Girón-González
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

Review 6.  Chronic Immune Activation in TB/HIV Co-infection.

Authors:  Riti Sharan; Allison N Bucşan; Shashank Ganatra; Mirko Paiardini; Mahesh Mohan; Smriti Mehra; Shabaana A Khader; Deepak Kaushal
Journal:  Trends Microbiol       Date:  2020-04-22       Impact factor: 17.079

7.  Naïve CD4+ cell counts significantly decay and high HIV RNA levels contribute to immunological progression in long-term non-progressors infected with HIV by blood products: a cohort study.

Authors:  Ling Xu; Yubin Liu; Xiaojing Song; Yanling Li; Yang Han; Ting Zhu; Wei Cao; Taisheng Li
Journal:  BMC Immunol       Date:  2021-06-03       Impact factor: 3.615

Review 8.  HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective.

Authors:  Loredana Sarmati; Gabriella D'Ettorre; Saverio Giuseppe Parisi; Massimo Andreoni
Journal:  Curr HIV Res       Date:  2015       Impact factor: 1.581

Review 9.  The Quest for Cellular Markers of HIV Reservoirs: Any Color You Like.

Authors:  Gilles Darcis; Ben Berkhout; Alexander O Pasternak
Journal:  Front Immunol       Date:  2019-09-20       Impact factor: 7.561

10.  Major influence of CD4 count at the initiation of cART on viral and immunological reservoir constitution in HIV-1 infected patients.

Authors:  Anne-Emmanuelle Depincé-Berger; Delphine Vergnon-Miszczycha; Alexandre Girard; Anne Frésard; Elisabeth Botelho-Nevers; Claude Lambert; Emilie Del Tedesco; Christian Genin; Bruno Pozzetto; Frédéric Lucht; Xavier Roblin; Thomas Bourlet; Stéphane Paul
Journal:  Retrovirology       Date:  2016-06-30       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.